{"gene":"GTF2E2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2016,"finding":"GTF2E2 encodes the beta subunit of TFIIE (TFIIEβ), which directly interacts with TFIIH to enable RNA polymerase II transcription initiation. Homozygous missense mutations (p.Ala150Pro and p.Asp187Tyr) in GTF2E2 destabilize the entire TFIIE complex, reducing protein levels of both TFIIEα and TFIIEβ subunits and decreasing phosphorylation of TFIIEα. TFIIE is not involved in nucleotide excision repair (NER), as UV-induced DNA damage repair was normal in GTF2E2-mutant cells.","method":"Patient cell lines with homozygous missense mutations, western blotting for protein levels, phosphorylation assays, UV damage repair assays","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal protein level measurements, phosphorylation assays, and NER functional assay in patient cells; replicated in two unrelated families with different mutations","pmids":["26996949"],"is_preprint":false},{"year":2017,"finding":"Mutant TFIIEβ (from GTF2E2 missense mutation) strongly reduces the total amount of the entire TFIIE complex and causes a temperature-sensitive transcription defect. In vitro erythroid differentiation of patient-derived iPS cells revealed a hematopoietic defect during late-stage differentiation associated with hemoglobin subunit imbalance, demonstrating a tissue-specific transcription deficiency independent of DNA repair.","method":"iPS cell reprogramming from patient fibroblasts, in vitro erythroid differentiation, western blotting, temperature-sensitivity assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (iPS differentiation, temperature-sensitivity, protein quantification) in patient-derived cells from two unrelated families","pmids":["28973399"],"is_preprint":false},{"year":2017,"finding":"GTF2E2 acts as a rate-limiting step in assembly of the TFIIE complex: depletion of GTF2E2 leads to decreased protein abundance of its complex partner GTF2E1, demonstrating post-transcriptional buffering of copy-number variation through complex stoichiometry control.","method":"Proteomics/genomics integration (CPTAC/TCGA datasets) with experimental confirmation of GTF2E2-GTF2E1 rate-limiting interaction","journal":"Cell systems","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — computational prediction confirmed experimentally, but abstract does not detail the specific experimental method used for confirmation","pmids":["29032074"],"is_preprint":false},{"year":2021,"finding":"GTF2E2 physically interacts with RPS4X, as identified by LC-MS/MS shotgun proteomics. Knockdown of GTF2E2 inhibited lung adenocarcinoma cell proliferation, migration, and invasion and promoted apoptosis in vitro, and attenuated tumor growth in vivo. GTF2E2's regulatory effect on LUAD development is mediated through RPS4X via the mTOR pathway.","method":"shRNA knockdown, LC-MS/MS proteomics for interacting proteins, in vitro proliferation/migration/invasion assays, xenograft in vivo model, mTOR pathway analysis","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — LC-MS/MS identifies physical interaction with RPS4X, and functional assays are consistent, but no direct biochemical reconstitution of the GTF2E2-RPS4X interaction or mechanistic dissection of mTOR pathway connection","pmids":["33757492"],"is_preprint":false},{"year":2021,"finding":"GTF2E2 positively interacts with the FUS promoter and regulates FUS expression transcriptionally. miR-139-5p represses GTF2E2 expression by downregulating its mRNA through binding with Argonaute 2 (Ago2). GTF2E2 promotes ESCC cell progression via activation of the AKT/ERK/mTOR pathway, and the phenotypic changes caused by GTF2E2 manipulation are recovered by rescuing FUS expression.","method":"Reporter/rescue assays, Ago2-binding assays for miR-139-5p, promoter interaction assays for FUS, in vitro cell proliferation/migration assays, in vivo xenograft, AKT/ERK/mTOR pathway analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — promoter interaction and Ago2 binding established by functional assays and rescue experiments; single lab but multiple orthogonal methods","pmids":["34853466"],"is_preprint":false},{"year":2023,"finding":"GTF2E2 transcriptionally regulates CCND1 expression, and glioblastoma progression is regulated through this axis. GTF2E2 is itself regulated by miR-340-5p directly or indirectly.","method":"CCK-8, colony formation, TUNEL, migration/wound-healing assays, xenograft model, miR-340-5p target validation","journal":"Cancer gene therapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, mechanistic details on CCND1 transcriptional regulation and miR-340-5p interaction are not rigorously detailed in abstract; 'directly or indirectly' indicates uncertainty","pmids":["37845349"],"is_preprint":false}],"current_model":"GTF2E2 encodes TFIIEβ, the beta subunit of the general transcription factor TFIIE, which forms a heterodimer with TFIIEα (GTF2E1) and directly interacts with TFIIH to enable RNA polymerase II transcription initiation; GTF2E2 acts as a rate-limiting subunit for TFIIE complex assembly, destabilizing mutations cause temperature-sensitive transcription defects and tissue-specific differentiation failures (notably in erythropoiesis) without impairing nucleotide excision repair, and in cancer contexts GTF2E2 has been shown to interact with RPS4X and to transcriptionally regulate FUS and CCND1 via the AKT/ERK/mTOR pathway."},"narrative":{"mechanistic_narrative":"GTF2E2 encodes TFIIEβ, the beta subunit of the general transcription factor TFIIE, which directly interacts with TFIIH to enable RNA polymerase II transcription initiation [PMID:26996949]. TFIIEβ functions as a rate-limiting subunit for TFIIE complex assembly: its depletion lowers the abundance of its heterodimeric partner GTF2E1 (TFIIEα), reflecting stoichiometric buffering of complex levels [PMID:29032074], and destabilizing homozygous missense mutations reduce levels of both subunits, decrease TFIIEα phosphorylation, and produce a temperature-sensitive transcription defect [PMID:26996949, PMID:28973399]. These mutations cause tissue-specific differentiation failures—most notably a late-stage erythroid/hematopoietic defect with hemoglobin subunit imbalance—while leaving nucleotide excision repair of UV damage intact, establishing that the phenotype is a transcription deficiency rather than a DNA repair defect [PMID:26996949, PMID:28973399]. In cancer contexts, GTF2E2 has been reported to physically associate with RPS4X and to act through mTOR signaling in lung adenocarcinoma [PMID:33757492], and to transcriptionally regulate target genes including FUS via AKT/ERK/mTOR signaling in esophageal carcinoma [PMID:34853466]. Beyond these findings, structural and biochemical details of how TFIIEβ engages the preinitiation complex are not further characterized in the available corpus.","teleology":[{"year":2016,"claim":"Established GTF2E2 as TFIIEβ and showed that its missense mutations destabilize the whole TFIIE complex while sparing DNA repair, separating transcription from NER function.","evidence":"Patient cell lines with homozygous missense mutations, western blotting, phosphorylation and UV-repair assays","pmids":["26996949"],"confidence":"High","gaps":["Does not resolve the structural basis of TFIIE–TFIIH interaction","Mechanism linking complex destabilization to specific gene programs not defined"]},{"year":2017,"claim":"Demonstrated that mutant TFIIEβ causes a temperature-sensitive transcription defect with a tissue-specific (erythroid) differentiation failure, confirming a transcription-based, repair-independent pathology.","evidence":"Patient-derived iPS cells, in vitro erythroid differentiation, temperature-sensitivity and protein quantification","pmids":["28973399"],"confidence":"High","gaps":["Why erythropoiesis is selectively sensitive remains unexplained","Target genes driving the differentiation block not identified"]},{"year":2017,"claim":"Showed that GTF2E2 is rate-limiting for TFIIE assembly, with its level controlling GTF2E1 abundance through stoichiometric post-transcriptional buffering.","evidence":"Integration of CPTAC/TCGA proteomics-genomics with experimental confirmation of the GTF2E2–GTF2E1 interaction","pmids":["29032074"],"confidence":"Medium","gaps":["Specific experimental method for confirmation not detailed in abstract","Degradation mechanism of unassembled GTF2E1 not defined"]},{"year":2021,"claim":"Implicated GTF2E2 in cancer by identifying a physical RPS4X interaction and an mTOR-mediated pro-tumorigenic role in lung adenocarcinoma.","evidence":"shRNA knockdown, LC-MS/MS proteomics, proliferation/migration/invasion assays, xenografts, mTOR pathway analysis","pmids":["33757492"],"confidence":"Medium","gaps":["No biochemical reconstitution of the GTF2E2–RPS4X interaction","How a general transcription factor links to mTOR signaling is not mechanistically dissected"]},{"year":2021,"claim":"Showed GTF2E2 transcriptionally activates FUS and drives ESCC progression via AKT/ERK/mTOR, with miR-139-5p/Ago2 repressing GTF2E2.","evidence":"Promoter interaction and Ago2-binding assays, rescue experiments, in vitro and xenograft models, pathway analysis","pmids":["34853466"],"confidence":"Medium","gaps":["Direct promoter occupancy vs. indirect effect not fully separated","Single-lab finding without independent replication"]},{"year":2023,"claim":"Extended the cancer role by linking GTF2E2 to CCND1 transcriptional regulation and miR-340-5p control in glioblastoma.","evidence":"Proliferation, colony formation, TUNEL, migration assays, xenograft, miR-340-5p target validation","pmids":["37845349"],"confidence":"Low","gaps":["Direct vs. indirect CCND1 regulation unresolved ('directly or indirectly')","Single-lab, mechanistically thin","No biochemical demonstration of GTF2E2 binding the CCND1 promoter"]},{"year":null,"claim":"How TFIIEβ engages the RNA Pol II preinitiation complex and TFIIH at structural resolution, and how a core general transcription factor selectively shapes tissue-specific and oncogenic gene programs, remain open.","evidence":"No timeline discovery addresses these questions","pmids":[],"confidence":"Low","gaps":["No structural model of TFIIE in the PIC in the corpus","Mechanism of selective target gene control unexplained","Cancer-context interactions not reconciled with general transcription role"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140223","term_label":"general transcription initiation factor activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1]}],"complexes":["TFIIE"],"partners":["GTF2E1","RPS4X"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29084","full_name":"Transcription initiation factor IIE subunit beta","aliases":["General transcription factor IIE subunit 2"],"length_aa":291,"mass_kda":33.0,"function":"Recruits TFIIH to the initiation complex and stimulates the RNA polymerase II C-terminal domain kinase and DNA-dependent ATPase activities of TFIIH. Both TFIIH and TFIIE are required for promoter clearance by RNA polymerase","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P29084/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/GTF2E2","classification":"Common Essential","n_dependent_lines":1200,"n_total_lines":1208,"dependency_fraction":0.9933774834437086},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GTF2E2","total_profiled":1310},"omim":[{"mim_id":"616943","title":"TRICHOTHIODYSTROPHY 6, NONPHOTOSENSITIVE; TTD6","url":"https://www.omim.org/entry/616943"},{"mim_id":"613644","title":"ACTIVATING TRANSCRIPTION FACTOR 7-INTERACTING PROTEIN; ATF7IP","url":"https://www.omim.org/entry/613644"},{"mim_id":"602955","title":"TAF6 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 80-KD; TAF6","url":"https://www.omim.org/entry/602955"},{"mim_id":"601675","title":"TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1","url":"https://www.omim.org/entry/601675"},{"mim_id":"189964","title":"GENERAL TRANSCRIPTION FACTOR IIE, POLYPEPTIDE 2; GTF2E2","url":"https://www.omim.org/entry/189964"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GTF2E2"},"hgnc":{"alias_symbol":["TFIIE-B","FE","TF2E2"],"prev_symbol":[]},"alphafold":{"accession":"P29084","domains":[{"cath_id":"1.10.10.10","chopping":"69-138","consensus_level":"high","plddt":69.6117,"start":69,"end":138},{"cath_id":"1.10.10","chopping":"147-202","consensus_level":"high","plddt":82.8137,"start":147,"end":202}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29084","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29084-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29084-F1-predicted_aligned_error_v6.png","plddt_mean":68.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GTF2E2","jax_strain_url":"https://www.jax.org/strain/search?query=GTF2E2"},"sequence":{"accession":"P29084","fasta_url":"https://rest.uniprot.org/uniprotkb/P29084.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29084/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29084"}},"corpus_meta":[{"pmid":"29032074","id":"PMC_29032074","title":"Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer.","date":"2017","source":"Cell systems","url":"https://pubmed.ncbi.nlm.nih.gov/29032074","citation_count":95,"is_preprint":false},{"pmid":"26996949","id":"PMC_26996949","title":"GTF2E2 Mutations Destabilize the General Transcription Factor Complex TFIIE in Individuals with DNA Repair-Proficient Trichothiodystrophy.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26996949","citation_count":52,"is_preprint":false},{"pmid":"31374204","id":"PMC_31374204","title":"Bi-allelic TARS Mutations Are Associated with Brittle Hair Phenotype.","date":"2019","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31374204","citation_count":52,"is_preprint":false},{"pmid":"28973399","id":"PMC_28973399","title":"Trichothiodystrophy causative TFIIEβ mutation affects transcription in highly differentiated tissue.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28973399","citation_count":37,"is_preprint":false},{"pmid":"8786118","id":"PMC_8786118","title":"Integrated map of the chromosome 8p12-p21 region, a region involved in human cancers and Werner syndrome.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8786118","citation_count":35,"is_preprint":false},{"pmid":"22404213","id":"PMC_22404213","title":"Identification of cellular proteins required for replication of human immunodeficiency virus type 1.","date":"2012","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/22404213","citation_count":30,"is_preprint":false},{"pmid":"33757492","id":"PMC_33757492","title":"Knockdown of GTF2E2 inhibits the growth and progression of lung adenocarcinoma via RPS4X in vitro and in vivo.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33757492","citation_count":19,"is_preprint":false},{"pmid":"37845349","id":"PMC_37845349","title":"GTF2E2 downregulated by miR-340-5p inhibits the malignant progression of glioblastoma.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37845349","citation_count":6,"is_preprint":false},{"pmid":"36834727","id":"PMC_36834727","title":"Multi-Omics Approaches for Revealing the Epigenetic Regulation of Histone H3.1 during Spermatogonial Stem Cell Differentiation In Vitro.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36834727","citation_count":5,"is_preprint":false},{"pmid":"28978030","id":"PMC_28978030","title":"Genetic profile and biological implication of PIN2/TRF1-interacting telomerase inhibitor 1 (PinX1) in human cancers: an analysis using The Cancer Genome Atlas.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28978030","citation_count":5,"is_preprint":false},{"pmid":"34853466","id":"PMC_34853466","title":"GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34853466","citation_count":4,"is_preprint":false},{"pmid":"30580289","id":"PMC_30580289","title":"PIBIDS syndrome in two Brazilian siblings.","date":"2018","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/30580289","citation_count":3,"is_preprint":false},{"pmid":"35954157","id":"PMC_35954157","title":"Kidney Cancer Biomarker Selection Using Regularized Survival Models.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35954157","citation_count":1,"is_preprint":false},{"pmid":"9061915","id":"PMC_9061915","title":"A 2.8 megabase YAC contig spanning D8S339, which is tightly linked to the Werner syndrome locus.","date":"1997","source":"Genome","url":"https://pubmed.ncbi.nlm.nih.gov/9061915","citation_count":1,"is_preprint":false},{"pmid":"42004467","id":"PMC_42004467","title":"Exploring the common ferroptosis-related genes and molecular mechanisms in periodontitis and systemic sclerosis via integrated bioinformatics and experimental analysis.","date":"2026","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/42004467","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.17.24313718","title":"Exome wide association study for blood lipids in 1,158,017 individuals from diverse populations","date":"2024-09-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.17.24313718","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9726,"output_tokens":1777,"usd":0.027917,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8657,"output_tokens":2322,"usd":0.050667,"stage2_stop_reason":"end_turn"},"total_usd":0.078584,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"GTF2E2 encodes the beta subunit of TFIIE (TFIIEβ), which directly interacts with TFIIH to enable RNA polymerase II transcription initiation. Homozygous missense mutations (p.Ala150Pro and p.Asp187Tyr) in GTF2E2 destabilize the entire TFIIE complex, reducing protein levels of both TFIIEα and TFIIEβ subunits and decreasing phosphorylation of TFIIEα. TFIIE is not involved in nucleotide excision repair (NER), as UV-induced DNA damage repair was normal in GTF2E2-mutant cells.\",\n      \"method\": \"Patient cell lines with homozygous missense mutations, western blotting for protein levels, phosphorylation assays, UV damage repair assays\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal protein level measurements, phosphorylation assays, and NER functional assay in patient cells; replicated in two unrelated families with different mutations\",\n      \"pmids\": [\"26996949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Mutant TFIIEβ (from GTF2E2 missense mutation) strongly reduces the total amount of the entire TFIIE complex and causes a temperature-sensitive transcription defect. In vitro erythroid differentiation of patient-derived iPS cells revealed a hematopoietic defect during late-stage differentiation associated with hemoglobin subunit imbalance, demonstrating a tissue-specific transcription deficiency independent of DNA repair.\",\n      \"method\": \"iPS cell reprogramming from patient fibroblasts, in vitro erythroid differentiation, western blotting, temperature-sensitivity assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (iPS differentiation, temperature-sensitivity, protein quantification) in patient-derived cells from two unrelated families\",\n      \"pmids\": [\"28973399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GTF2E2 acts as a rate-limiting step in assembly of the TFIIE complex: depletion of GTF2E2 leads to decreased protein abundance of its complex partner GTF2E1, demonstrating post-transcriptional buffering of copy-number variation through complex stoichiometry control.\",\n      \"method\": \"Proteomics/genomics integration (CPTAC/TCGA datasets) with experimental confirmation of GTF2E2-GTF2E1 rate-limiting interaction\",\n      \"journal\": \"Cell systems\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — computational prediction confirmed experimentally, but abstract does not detail the specific experimental method used for confirmation\",\n      \"pmids\": [\"29032074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GTF2E2 physically interacts with RPS4X, as identified by LC-MS/MS shotgun proteomics. Knockdown of GTF2E2 inhibited lung adenocarcinoma cell proliferation, migration, and invasion and promoted apoptosis in vitro, and attenuated tumor growth in vivo. GTF2E2's regulatory effect on LUAD development is mediated through RPS4X via the mTOR pathway.\",\n      \"method\": \"shRNA knockdown, LC-MS/MS proteomics for interacting proteins, in vitro proliferation/migration/invasion assays, xenograft in vivo model, mTOR pathway analysis\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — LC-MS/MS identifies physical interaction with RPS4X, and functional assays are consistent, but no direct biochemical reconstitution of the GTF2E2-RPS4X interaction or mechanistic dissection of mTOR pathway connection\",\n      \"pmids\": [\"33757492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GTF2E2 positively interacts with the FUS promoter and regulates FUS expression transcriptionally. miR-139-5p represses GTF2E2 expression by downregulating its mRNA through binding with Argonaute 2 (Ago2). GTF2E2 promotes ESCC cell progression via activation of the AKT/ERK/mTOR pathway, and the phenotypic changes caused by GTF2E2 manipulation are recovered by rescuing FUS expression.\",\n      \"method\": \"Reporter/rescue assays, Ago2-binding assays for miR-139-5p, promoter interaction assays for FUS, in vitro cell proliferation/migration assays, in vivo xenograft, AKT/ERK/mTOR pathway analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — promoter interaction and Ago2 binding established by functional assays and rescue experiments; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"34853466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GTF2E2 transcriptionally regulates CCND1 expression, and glioblastoma progression is regulated through this axis. GTF2E2 is itself regulated by miR-340-5p directly or indirectly.\",\n      \"method\": \"CCK-8, colony formation, TUNEL, migration/wound-healing assays, xenograft model, miR-340-5p target validation\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, mechanistic details on CCND1 transcriptional regulation and miR-340-5p interaction are not rigorously detailed in abstract; 'directly or indirectly' indicates uncertainty\",\n      \"pmids\": [\"37845349\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GTF2E2 encodes TFIIEβ, the beta subunit of the general transcription factor TFIIE, which forms a heterodimer with TFIIEα (GTF2E1) and directly interacts with TFIIH to enable RNA polymerase II transcription initiation; GTF2E2 acts as a rate-limiting subunit for TFIIE complex assembly, destabilizing mutations cause temperature-sensitive transcription defects and tissue-specific differentiation failures (notably in erythropoiesis) without impairing nucleotide excision repair, and in cancer contexts GTF2E2 has been shown to interact with RPS4X and to transcriptionally regulate FUS and CCND1 via the AKT/ERK/mTOR pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GTF2E2 encodes TFIIEβ, the beta subunit of the general transcription factor TFIIE, which directly interacts with TFIIH to enable RNA polymerase II transcription initiation [#0]. TFIIEβ functions as a rate-limiting subunit for TFIIE complex assembly: its depletion lowers the abundance of its heterodimeric partner GTF2E1 (TFIIEα), reflecting stoichiometric buffering of complex levels [#2], and destabilizing homozygous missense mutations reduce levels of both subunits, decrease TFIIEα phosphorylation, and produce a temperature-sensitive transcription defect [#0, #1]. These mutations cause tissue-specific differentiation failures—most notably a late-stage erythroid/hematopoietic defect with hemoglobin subunit imbalance—while leaving nucleotide excision repair of UV damage intact, establishing that the phenotype is a transcription deficiency rather than a DNA repair defect [#0, #1]. In cancer contexts, GTF2E2 has been reported to physically associate with RPS4X and to act through mTOR signaling in lung adenocarcinoma [#3], and to transcriptionally regulate target genes including FUS via AKT/ERK/mTOR signaling in esophageal carcinoma [#4]. Beyond these findings, structural and biochemical details of how TFIIEβ engages the preinitiation complex are not further characterized in the available corpus.\",\n  \"teleology\": [\n    {\n      \"year\": 2016,\n      \"claim\": \"Established GTF2E2 as TFIIEβ and showed that its missense mutations destabilize the whole TFIIE complex while sparing DNA repair, separating transcription from NER function.\",\n      \"evidence\": \"Patient cell lines with homozygous missense mutations, western blotting, phosphorylation and UV-repair assays\",\n      \"pmids\": [\"26996949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve the structural basis of TFIIE–TFIIH interaction\", \"Mechanism linking complex destabilization to specific gene programs not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that mutant TFIIEβ causes a temperature-sensitive transcription defect with a tissue-specific (erythroid) differentiation failure, confirming a transcription-based, repair-independent pathology.\",\n      \"evidence\": \"Patient-derived iPS cells, in vitro erythroid differentiation, temperature-sensitivity and protein quantification\",\n      \"pmids\": [\"28973399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why erythropoiesis is selectively sensitive remains unexplained\", \"Target genes driving the differentiation block not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed that GTF2E2 is rate-limiting for TFIIE assembly, with its level controlling GTF2E1 abundance through stoichiometric post-transcriptional buffering.\",\n      \"evidence\": \"Integration of CPTAC/TCGA proteomics-genomics with experimental confirmation of the GTF2E2–GTF2E1 interaction\",\n      \"pmids\": [\"29032074\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific experimental method for confirmation not detailed in abstract\", \"Degradation mechanism of unassembled GTF2E1 not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated GTF2E2 in cancer by identifying a physical RPS4X interaction and an mTOR-mediated pro-tumorigenic role in lung adenocarcinoma.\",\n      \"evidence\": \"shRNA knockdown, LC-MS/MS proteomics, proliferation/migration/invasion assays, xenografts, mTOR pathway analysis\",\n      \"pmids\": [\"33757492\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No biochemical reconstitution of the GTF2E2–RPS4X interaction\", \"How a general transcription factor links to mTOR signaling is not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed GTF2E2 transcriptionally activates FUS and drives ESCC progression via AKT/ERK/mTOR, with miR-139-5p/Ago2 repressing GTF2E2.\",\n      \"evidence\": \"Promoter interaction and Ago2-binding assays, rescue experiments, in vitro and xenograft models, pathway analysis\",\n      \"pmids\": [\"34853466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter occupancy vs. indirect effect not fully separated\", \"Single-lab finding without independent replication\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended the cancer role by linking GTF2E2 to CCND1 transcriptional regulation and miR-340-5p control in glioblastoma.\",\n      \"evidence\": \"Proliferation, colony formation, TUNEL, migration assays, xenograft, miR-340-5p target validation\",\n      \"pmids\": [\"37845349\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Direct vs. indirect CCND1 regulation unresolved ('directly or indirectly')\", \"Single-lab, mechanistically thin\", \"No biochemical demonstration of GTF2E2 binding the CCND1 promoter\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TFIIEβ engages the RNA Pol II preinitiation complex and TFIIH at structural resolution, and how a core general transcription factor selectively shapes tissue-specific and oncogenic gene programs, remain open.\",\n      \"evidence\": \"No timeline discovery addresses these questions\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of TFIIE in the PIC in the corpus\", \"Mechanism of selective target gene control unexplained\", \"Cancer-context interactions not reconciled with general transcription role\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140223\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [\"TFIIE\"],\n    \"partners\": [\"GTF2E1\", \"RPS4X\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":3,"faith_total":4,"faith_pct":75.0}}